Silence Therapeutics plc (SLNCF PINK) stock market data APIs
$1.4826
0(0%)
as of March 21, 2025
Silence Therapeutics plc Financial Data Overview
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Prev. Close
1.4826
Open
1.4826
High
1.4826
Low
1.4826
52 wk Range
1.01-14.75
Market Cap
208 M
Shares Outstanding
142 M
Revenue
43 258 K
EPS
-0.191
Beta
1.072
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Silence Therapeutics plc data using free add-ons & libraries
Get Silence Therapeutics plc Fundamental Data
Silence Therapeutics plc Fundamental data includes:
- Net Revenue: 43 258 K
- EBITDA: -48 989 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-09-30
- EPS/Forecast: -0.11
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Silence Therapeutics plc News
New
Insiders the biggest winners as Silence Therapeutics plc's (NASDAQ:SLN) market cap rises to US$736m
Key Insights Significant insider control over Silence Therapeutics implies vested interests in company growth 53% of the business is held by the top 4 shareholders Institutions own 24% of Silence The...
All You Need to Know About Silence Therapeutics PLC Sponsored ADR (SLN) Rating Upgrade to Strong Buy
Silence Therapeutics PLC Sponsored ADR (SLN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in ea...
Silence Therapeutics PLC Sponsored ADR (SLN) Is a Great Choice for 'Trend' Investors, Here's Why
While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the ...
This Silence Therapeutics Insider Increased Their Holding In The Last Year
Looking at Silence Therapeutics plc's (NASDAQ:SLN ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
